Gemcitabine and lenalidomide combination in a patient with metastatic pancreatic cancer: A case study

Medical Oncology

Volumn 27, Issue 2, 2010, Pages 430-433

  Liu, Wai M ^a   Nizar, Shiyam ^a   Dalgleish, Angus G ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Drug combination therapy; Gemcitabine; Lenalidomide; Pancreatic cancer

Indexed keywords

CA 19-9 ANTIGEN; GEMCITABINE; LENALIDOMIDE; TUMOR MARKER;

AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW DEPRESSION; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG POTENTIATION; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN CELL; INCIDENTAL FINDING; INFECTION; LIVER METASTASIS; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SPLEEN TUMOR; TREATMENT RESPONSE;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; FEMALE; HUMANS; PANCREATIC NEOPLASMS; THALIDOMIDE;

EID: 77956929109     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12032-009-9228-6     Document Type: Article

References (12)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71-96. doi: 10.3322/CA.2007.0010.
2. Hariharan D, Saied A, Kocher HM. Analysis of mortality rates for pancreatic cancer across the world. HPB (Oxford). 2008; 10:58-62.
3. Office National Statistics: xsdataset.asp?vlnk=982&Pos=&ColRank= 1&Rank=544. Accessed 23 Oct 2008.
4. Fryer RA, Galustian C, Dalgleish AG. Recent advances and developments in treatment strategies against pancreatic cancer. Curr Clin Pharmacol. 2009;4:102-12.
5. Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403-13.
6. Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet. 2004;363:1049-57. doi:10.1016/S0140-6736(04)15841-8. (Pubitemid 38410779)
7. Bartlett JB, Michael A, Clarke IA, Dredge K, Nicholson S, Kristeleit H, et al. Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers. Br J Cancer. 2004;90:955-61. doi: 10.1038/sj.bjc.6601579. (Pubitemid 38495811)
8. Liu WM. Enhancing the cytotoxic activity of novel targeted therapies-is there a role for a combinatorial approach? Curr Clin Pharmacol. 2008;3:108-17. doi:10.2174/157488408784293714.
9. Bronte V, Apolloni E, Cabrelle A, Ronca R, Serafini P, Zamboni P, et al. Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells. Blood. 2000;96:3838-46.
10. Serafini P, De Santo C, Marigo I, Cingarlini S, Dolcetti L, Gallina G, et al. Derangement of immune responses by myeloid suppressor cells. Cancer Immunol Immunother. 2004;53:64-72. doi: 10.1007/s00262-003-0443-2. (Pubitemid 38161211)
11. Suzuki E, Kapoor V, Jassar AS, Kaiser LR, Albelda SM. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res. 2005;11:6713-21. doi: 10.1158/1078-0432.CCR-05-0883. (Pubitemid 41339014)
12. Bartlett JB, Dredge K, Dalgleish AG. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer. 2004;4:314-22. doi:10.1038/nrc1323.